Assessing Response Durability and Survival After Second-Line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk Model
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new risk model predicts overall survival and response duration for metastatic urothelial carcinoma (UC) patients receiving second-line pembrolizumab. The model identifies patients who may benefit from alternative treatments.
Area Of Science
- Oncology
- Immunotherapy
- Clinical Trial Design
Background
- Metastatic urothelial carcinoma (UC) is a challenging diagnosis.
- Pembrolizumab has shown efficacy as a second-line treatment for advanced UC.
- Predictive models are needed to personalize treatment strategies and improve patient outcomes.
Purpose Of The Study
- To develop and validate a risk model for predicting overall survival (OS) and response duration in patients with advanced UC treated with second-line pembrolizumab.
- To identify clinical factors associated with treatment outcomes.
- To stratify patients into risk groups for tailored therapeutic decisions.
Main Methods
- Retrospective analysis of 565 patients with advanced UC treated with second-line pembrolizumab.
- Univariate and multivariate Cox regression to identify predictors of time to progression (TTP).
- Development of a risk model based on independent TTP predictors and validation in an independent cohort.
Main Results
- Key predictors of inferior TTP included short interval from prior chemotherapy (<6 months), liver metastasis, and poor ECOG Performance Status (>1).
- The validated risk model stratified patients into favorable, intermediate, and poor-risk groups, demonstrating significant differences in median OS (21.6, 11.7, and 4.9 months, respectively).
- Response duration also varied significantly across risk groups, with median durations of 38.9, 13.8, and 7.8 months for favorable, intermediate, and poor-risk groups, respectively.
Conclusions
- A validated risk model effectively predicts OS and response durability for advanced UC patients receiving second-line pembrolizumab.
- The model can aid in identifying patients who may require alternative treatment strategies, particularly those in the poor-risk group.
- This tool supports personalized medicine approaches in advanced urothelial carcinoma treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...